Rosiglitazone
Rosiglitazone
Rosiglitazone (pronounced roh-si-glit-uh-zohn) is an antidiabetic drug in the thiazolidinedione class of drugs. It is marketed by the pharmaceutical company GlaxoSmithKline as a stand-alone drug or for use in combination with metformin or with sulfonylurea.
Etymology
The name "Rosiglitazone" is derived from parts of its chemical structure. "Ros" is short for rosaniline, a compound used in the synthesis of the drug. "Gli" is derived from glitazone, the class of drugs to which Rosiglitazone belongs.
Usage
Rosiglitazone is used to treat type 2 diabetes. It works by making the body's cells more sensitive to insulin, which helps the body use glucose more effectively.
Side Effects
Common side effects of Rosiglitazone include headache, muscle pain, and sore throat. Serious side effects can include heart failure and liver disease.
Related Terms
- Antidiabetic drug
- Thiazolidinedione
- Metformin
- Sulfonylurea
- Type 2 diabetes
- Insulin
- Glucose
- Heart failure
- Liver disease
External links
- Medical encyclopedia article on Rosiglitazone
- Wikipedia's article - Rosiglitazone
This WikiMD article is a stub. You can help make it a full article.
Languages: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski